Nothing Special   »   [go: up one dir, main page]

ES2191032T3 - Oncoproteina protein-quinasa. - Google Patents

Oncoproteina protein-quinasa.

Info

Publication number
ES2191032T3
ES2191032T3 ES94922622T ES94922622T ES2191032T3 ES 2191032 T3 ES2191032 T3 ES 2191032T3 ES 94922622 T ES94922622 T ES 94922622T ES 94922622 T ES94922622 T ES 94922622T ES 2191032 T3 ES2191032 T3 ES 2191032T3
Authority
ES
Spain
Prior art keywords
jnk
kinase
jun
activation domain
terminal activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94922622T
Other languages
English (en)
Inventor
Michael Karin
Masahiko Hibi
Anning Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2191032(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/094,533 external-priority patent/US5534426A/en
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2191032T3 publication Critical patent/ES2191032T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO AISLADO (JNK) QUE SE CARACTERIZA PORQUE TIENE UN PESO MOLECULAR DE 46KD SEGUN QUEDA DETERMINADO UTILIZANDO UN GEL REDUCIDO SDS-PAGE, QUE TIENE LA ACTIVIDAD SERINA TREONINA QUINASA, FOSFORILANDO EL DOMINIO DE ACTIVACION N-TERMINAL DE C-JUN Y SECUENCIAS DE POLINUCLEOTIDOS Y UN METODO PARA LA DETECCION DEL JNK. JNK FOSFORILA EL DOMINIO DE ACTIVACION N-TERMINAL DE C-JUN QUE AFECTA A LA EXPRESION DE GENES DE LAS REGIONES AP-1.
ES94922622T 1993-07-19 1994-07-18 Oncoproteina protein-quinasa. Expired - Lifetime ES2191032T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/094,533 US5534426A (en) 1993-07-19 1993-07-19 Oncoprotein protein kinase
US08/220,602 US6514745B1 (en) 1993-07-19 1994-03-25 Oncoprotein protein kinase

Publications (1)

Publication Number Publication Date
ES2191032T3 true ES2191032T3 (es) 2003-09-01

Family

ID=26788998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94922622T Expired - Lifetime ES2191032T3 (es) 1993-07-19 1994-07-18 Oncoproteina protein-quinasa.

Country Status (11)

Country Link
US (7) US6514745B1 (es)
EP (2) EP0726908A4 (es)
JP (3) JP2986548B2 (es)
AT (1) ATE233785T1 (es)
AU (2) AU685484B2 (es)
CA (2) CA2167302A1 (es)
DE (1) DE69432223T2 (es)
DK (1) DK0728143T3 (es)
ES (1) ES2191032T3 (es)
PT (1) PT728143E (es)
WO (2) WO1995003323A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
US6001584A (en) 1993-07-19 1999-12-14 The Regents Of The University Of California Oncoprotein protein kinase
US6846644B2 (en) * 1993-07-19 2005-01-25 The Regents Of The University Of California Oncoprotein protein kinase
US5925557A (en) * 1994-09-29 1999-07-20 The Regents Of The University Of California DNA encoding mitogen activated protein kinase, FRK
US6132978A (en) * 1995-12-19 2000-10-17 National Jewish Medical And Research Center Method to regulate CD40 signaling
DE69731210T2 (de) * 1996-08-16 2005-10-20 Genencor International, Inc., Palo Alto Expressionssystem abgeleitet von der lipase-regulationskaskade von pseudonomas alcaligenes
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
AU6472998A (en) 1997-03-28 1998-10-22 Research Foundation Of The State University Of New York, The Antisense oligonucleotides for mitogen-activated protein kinases as therapy for breast cancer
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
EP1820854B1 (en) * 1997-10-03 2010-07-28 University of Massachusetts JNK3 modulators and methods of use
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
DE69933856D1 (de) * 1998-02-13 2006-12-14 Koester Hubert Verwendung von ribozymen zur bestimmung der funktion von genen
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
EP0984070A1 (en) * 1998-08-31 2000-03-08 Boehringer Ingelheim International GmbH Method for identifying substances for the treatment of disorders associated with c-Jun-mediated apoptosis
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
FR2788531B1 (fr) * 1999-01-20 2003-01-31 Aventis Pharma Sa Nouveaux polypeptides derives de la proteine jnk3 humaine, leurs variants, les sequences nucleotidiques correspondantes, et leurs utilisations
CA2358914A1 (fr) * 1999-01-20 2000-07-27 Francine Desanlis Cremond Polypeptides derives de jnk3
WO2001000677A1 (en) 1999-06-28 2001-01-04 The University Of Newcastle Research Associates Limited A method of modulating integrin mediated cellular activity and agents useful for same
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7232897B2 (en) * 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
US20040185460A1 (en) * 2001-05-24 2004-09-23 Angeles Thelma S Novel mixed lineage kinase (7) (mlk7) polypeptide polynucleotides encoding the same and methods of use thereof
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
WO2004026407A1 (en) * 2002-09-06 2004-04-01 Institut Curie Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1626714B1 (en) * 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
US20050020391A1 (en) * 2003-07-17 2005-01-27 Pinnacle Sports Equipment Co., Inc. Bamboo bat and method of manufacture
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
AU2004281077B2 (en) 2003-10-17 2010-12-02 Inter-K Pty Limited Methods and agents for the treatment of cancer
UA91676C2 (ru) * 2004-04-08 2010-08-25 Эплайд Рисерч Системз Эрс Холдинг Н.В. Композиция, которая содержит ингибитор jnk и циклоспорин
AU2007356036A1 (en) * 2007-06-29 2009-01-08 Newsouth Innovations Pty Limited Treatment of rheumatoid arthritis
WO2009103127A1 (en) * 2008-02-22 2009-08-27 Inter-K Pty Limited Therapeutic peptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599077A3 (en) * 1992-10-29 1994-11-23 Yeda Res & Dev Antimetastatic vaccine.

Also Published As

Publication number Publication date
JPH09500535A (ja) 1997-01-21
US5994513A (en) 1999-11-30
US6514745B1 (en) 2003-02-04
EP0728143A4 (en) 1999-04-21
EP0728143B1 (en) 2003-03-05
EP0726908A4 (en) 1999-04-07
DK0728143T3 (da) 2003-07-07
WO1995003324A1 (en) 1995-02-02
AU7338094A (en) 1995-02-20
AU700137B2 (en) 1998-12-24
JP3745558B2 (ja) 2006-02-15
EP0728143A1 (en) 1996-08-28
US5804399A (en) 1998-09-08
JP2000023681A (ja) 2000-01-25
US6193965B1 (en) 2001-02-27
PT728143E (pt) 2003-06-30
ATE233785T1 (de) 2003-03-15
US5593884A (en) 1997-01-14
US5837244A (en) 1998-11-17
AU685484B2 (en) 1998-01-22
JP2925740B2 (ja) 1999-07-28
DE69432223D1 (de) 2003-04-10
CA2167302A1 (en) 1995-02-02
US5605808A (en) 1997-02-25
CA2166981C (en) 2000-11-07
JP2986548B2 (ja) 1999-12-06
AU7366894A (en) 1995-02-20
EP0726908A1 (en) 1996-08-21
WO1995003323A1 (en) 1995-02-02
DE69432223T2 (de) 2003-08-21
JPH09507384A (ja) 1997-07-29

Similar Documents

Publication Publication Date Title
ES2191032T3 (es) Oncoproteina protein-quinasa.
HUT77431A (hu) Fonálféregből kivont szerinproteáz-inhibitorok és véralvadásgátló proteinek
ATE273718T1 (de) Methoxyethoxy-oligonukleotide zur regulierung der proteinkinase c expression
DE69825066D1 (de) Veränderte proteinkinasen, die modifizierte nukleotidtriphosphat substrate verwenden können
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
NO893054D0 (no) Fremgangsmaate for utdypning av nukleotidsekvenser.
FI913169A (fi) Oligonukleotidanaloger med terminala 3'-3'- eller 5'-5'-internukleotidkopplingar.
FR2602776B1 (fr) Diorganopolysiloxane a fonction beta-cetoester utile comme stabilisant des polymeres a base de polychlorure de vinyle
ATE412052T1 (de) Synthetische polynukleotide
DK1383903T3 (da) Fremgangsmåder til fremstilling af askorbinsyre-intermediater i vært-celler
ATE268750T1 (de) Proteintyrosinphosphatase inhibitoren
NO900607L (no) Enzymatisk oppvaskmiddel.
DE69418387D1 (de) Neo-Diol Phosphite als Polymer-Stabilisatoren
FI880588A (fi) Interpolymerkompositioner och membraner av eten-akrylsyratyp, vilka har foerbaettrad glidbarhet och foerminskad faestfoermaoga.
DE69432120D1 (de) Mit chemotherapeutische zusammensetzungenassoziierten genetischen suppressor-elementen
DE69635446D1 (de) Pflanzenpromoter und dessen verwendung zur genexpression
DE60016405D1 (de) Neurodegenerative-erkrankung verwandtes gen
DE59008462D1 (de) Stabilisatordispersionen.
DE60025380D1 (de) Ein-schritttest zum nachweis von antimikrobiellen rückständen in eiern
FR2654430B1 (fr) Nouveaux derives de peptides, utilisables comme inhibiteurs des collagenases bacteriennes.
ES1042740U (es) Elemento limitador de movimiento.
DE3881321D1 (de) Octapeptide als hemmer myristoylierender enzyme.
ATE89828T1 (de) Octapeptide als hemmer myristoylierender enzyme.
IT8920827A0 (it) Sequenze di nucleotidi.
ES1012184Y (es) Nueva escopeta de caza.